title: Usefulness of Iron Deficiency Correction in Management of Patients With Heart Failure [from the Registry Analysis of Iron Deficiency-Heart Failure (RAID-HF) Registry].
abstract: Iron deficiency (ID) has been identified as an important co-morbidity in patients with heart failure (HF). Intravenous iron therapy reduced symptoms and rehospitalizations of iron-deficient patients with HF in randomized trials. The present multicenter study investigated the "real-world" management of iron status in patients with HF. Consecutive patients with HF and ejection fraction ≤40% were recruited and analyzed from December 2010 to October 2015 by 11 centers in Germany and Switzerland. Of 1,484 patients with HF, iron status was determined in only 923 patients (62.2%), despite participation of the centers in a registry focusing on ID and despite guideline recommendation to determine iron status. In patients with determined iron status, a prevalence of 54.7% (505 patients) for ID was observed. Iron therapy was performed in only 8.5% of the iron-deficient patients with HF; 2.6% were treated with intravenous iron therapy. The patients with iron therapy were characterized by a high rate of symptomatic HF and anemia. In conclusion, despite strong evidence of beneficial effects of iron therapy on symptoms and rehospitalizations, diagnostic and therapeutic efforts on ID in HF are low in the actual clinical practice, and the awareness to diagnose and treat ID in HF should be strongly enforced.
authors.affiliation: Bremer Institut für Herz- und Kreislaufforschung am Klinikum Links der Weser, Bremen, Germany. Electronic address: harm.wienbergen@klinikum-bremen-ldw.de.
authors.forename: Harm
authors.initials: H
authors.lastname: Wienbergen
authors.affiliation: Universitätsspital Basel, Kardiologie, Basel, Switzerland.
authors.forename: Otmar
authors.initials: O
authors.lastname: Pfister
authors.affiliation: Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Hochadel
authors.affiliation: Bremer Institut für Herz- und Kreislaufforschung am Klinikum Links der Weser, Bremen, Germany.
authors.forename: Stephan
authors.initials: S
authors.lastname: Michel
authors.affiliation: Elisabeth-Krankenhaus Essen, Klinik für Kardiologie und Angiologie, Essen, Germany.
authors.forename: Oliver
authors.initials: O
authors.lastname: Bruder
authors.affiliation: Herz- und Gefäßzentrum Bad Bevensen, Klinik für Kardiologie, Bad Bevensen, Germany.
authors.forename: Björn Andrew
authors.initials: BA
authors.lastname: Remppis
authors.affiliation: Kantonsspital St. Gallen, Klinik für Kardiologie, St. Gallen, Switzerland.
authors.forename: Micha Tobias
authors.initials: MT
authors.lastname: Maeder
authors.affiliation: Technische Universität Dresden, Herzzentrum, Dresden, Germany.
authors.forename: Ruth
authors.initials: R
authors.lastname: Strasser
authors.affiliation: Klinikum Augsburg, 1. Medizinische Klinik, Augsburg, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: von Scheidt
authors.affiliation: Klinikum Nürnberg, Medizinische Klinik 8, Nürnberg, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Pauschinger
authors.affiliation: Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.
authors.forename: Jochen
authors.initials: J
authors.lastname: Senges
authors.affiliation: Bremer Institut für Herz- und Kreislaufforschung am Klinikum Links der Weser, Bremen, Germany.
authors.forename: Rainer
authors.initials: R
authors.lastname: Hambrecht
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D002097:C-Reactive Protein / Q000378:metabolism; D015331:Cohort Studies; D019468:Disease Management; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use; D005858:Germany / Q000453:epidemiology; D006333:Heart Failure / Q000150:complications / Q000628:therapy*; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008320:Maltose / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D015999:Multivariate Analysis; D020097:Natriuretic Peptide, Brain / Q000097:blood; D016017:Odds Ratio; D010446:Peptide Fragments / Q000097:blood; D015995:Prevalence; D012042:Registries; D013557:Switzerland / Q000453:epidemiology; D014131:Trace Elements / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005290:Ferric Compounds; D010446:Peptide Fragments; D014131:Trace Elements; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; C522335:ferric carboxymaltose; D008320:Maltose; D002097:C-Reactive Protein; D007501:Iron